MCID: PNC035
MIFTS: 84

Pancreatic Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer 54 38 12 50 24 71 13 13 13 52 41 14
Pancreatic Carcinoma 12 50 24 71 52 42 14 69
Familial Pancreatic Carcinoma 50 24 56 29
Familial Pancreatic Cancer 50 24 56
Pancreatic Carcinoma, Familial 12 69
Pancreatic Acinar Carcinoma 24 71
Pancreatic Cancer, Somatic 54 24
Carcinoma of Pancreas 12 29
Pancreatic Neoplasm 12 69
Pancreatic Tumor 12 52
Malignant Neoplasm of Body of Pancreas 12
Malignant Neoplasm of Head of Pancreas 12
Malignant Neoplasm of Tail of Pancreas 12
Hereditary Pancreatic Carcinoma 50
Malignant Neoplasm of Pancreas 69
Pancreatic Carcinoma, Somatic 54
Hereditary Pancreatic Cancer 50
Exocrine Pancreas Carcinoma 12
Neoplasm of the Pancreas 29
Cancer of the Pancreas 50
Pancreatic Neoplasms 42
Ca Body of Pancreas 12
Ca Head of Pancreas 12
Ca Tail of Pancreas 12
Pancreas Carcinoma 50
Pancreas Neoplasm 12
Exocrine Cancer 12
Pancreas Cancer 50
Pnca 71

Characteristics:

Orphanet epidemiological data:

56
familial pancreatic carcinoma
Inheritance: Multigenic/multifactorial; Age of onset: Adult;

OMIM:

54
Inheritance:
autosomal dominant
somatic mutation
multifactorial

Miscellaneous:
may be seen with other forms of cancer in a family


HPO:

32
pancreatic cancer:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



Summaries for Pancreatic Cancer

NIH Rare Diseases : 50 familial pancreatic cancer (fpc) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). it is sometimes referred to as fpc only when there is not a known hereditary cancer syndrome in an affected family. in familial cases, pancreatic cancer often occurs before age 50 (earlier than other forms of pancreatic cancer). in 60% of cases it occurs within the head of the pancreas. symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. a specific genetic cause of fpc (in the absence of a known syndrome) has not been identified. familial cases of pancreatic cancer due to hereditary conditions may be caused by mutations in any of several genes. individuals who carry a mutation in one of these genes are often at an increased risk of other types of cancers as well. currently, only 10-20% of families with fpc will have a mutation identified by genetic testing. hereditary cancer syndromes and other inherited conditions associated with pancreatic cancer include:brca1 hereditary breast and ovarian cancer syndrome brca2 hereditary breast and ovarian cancer syndrome peutz-jeghers syndrome fammm syndrome lynch syndrome hereditary pancreatitis in many cases, inheritance of fpc is autosomal dominant; in some cases, is may be multifactorial. it is important to note that pancreatic cancer itself is not inherited, but a genetic predisposition to developing cancer is inherited. treatment may include surgical resection, chemotherapy, and/or radiotherapy. resection is the only potential cure, but most patients have advanced, non-resectable tumors by the time of diagnosis. last updated: 9/27/2016

MalaCards based summary : Pancreatic Cancer, also known as pancreatic carcinoma, is related to pancreatic cancer 4 and tropical calcific pancreatitis, and has symptoms including neoplasm of the pancreas, abdominal pain and constipation. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Pancreatic cancer and ERK Signaling. The drugs Afinitor and Erbitux have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and liver, and related phenotypes are Decreased homologous recombination repair frequency and digestive/alimentary

Disease Ontology : 12 An endocrine gland cancer located in the pancreas.

OMIM : 54
Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350)

MedlinePlus : 41 the pancreas is a gland behind your stomach and in front of your spine. it produces the juices that help break down food and the hormones that help control blood sugar levels. pancreatic cancer usually begins in the cells that produce the juices. some risk factors for developing pancreatic cancer include smoking long-term diabetes chronic pancreatitis certain hereditary disorders pancreatic cancer is hard to catch early. it doesn't cause symptoms right away. when you do get symptoms, they are often vague or you may not notice them. they include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. possible treatments include surgery, radiation, chemotherapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

UniProtKB/Swiss-Prot : 71 Pancreatic cancer: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Wikipedia : 72 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
id Related Disease Score Top Affiliating Genes
1 pancreatic cancer 4 35.0 BRCA1 BRCA2
2 tropical calcific pancreatitis 33.2 BRCA2 MUC4 SPINK1 SST
3 colorectal cancer 31.9 BRCA1 BRCA2 CCKBR CCND1 CDKN1A CDKN2A
4 prostate cancer 31.5 BRCA1 BRCA2 CCND1 CDKN1A EGF EGFR
5 lung cancer 31.5 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
6 atrophic gastritis 31.5 CDKN1A CDKN2A TP53
7 pancreatic cancer/melanoma syndrome 12.1
8 pancreatic cancer 3 12.1
9 pancreatic cancer 1 12.1
10 pancreatic cancer 2 12.0
11 osteoclast-like giant cell neoplasm of the pancreas 12.0
12 adenosquamous pancreas carcinoma 11.9
13 pancreatic cancer susceptibility 4 11.8
14 exudative vitreoretinopathy 7 11.8 BRCA1 BRCA2 CCND1 CDKN1A CDKN2A EGF
15 pancreatic cancer susceptibility 2 11.7
16 pancreatic cancer, childhood 11.7
17 pancreatic cancer susceptibility 1 11.7
18 lethal congenital contracture syndrome 10 11.7 BRCA1 BRCA2 CCND1 CDKN1A CDKN2A EGF
19 gastric fundus cancer 11.7 CCKBR CCND1 CDKN1A CDKN2A EGF EGFR
20 sertoli-leydig cell tumor 11.7 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
21 nail disorder, nonsyndromic congenital, 1 11.7 BRCA1 BRCA2 CCND1 CDKN1A CDKN2A EGF
22 bardet-biedl syndrome 11.7 BRCA1 BRCA2 CCND1 CDKN1A CDKN2A EGF
23 trachea squamous cell carcinoma 11.7 BRCA1 BRCA2 CCND1 CDKN2A EGFR KRAS
24 gallbladder cancer 11.6 CCND1 CDKN1A CDKN2A EGFR KRAS SMAD4
25 nail disorder, nonsyndromic congenital, 3, 11.6 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
26 paroxysmal nocturnal hemoglobinuria 11.6 CCND1 CDKN2A EGFR KRAS MUC4 SMAD4
27 cervical cancer, somatic 11.6 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
28 gastric cancer, somatic 11.6 CCKBR CCND1 CDKN1A CDKN2A EGFR KRAS
29 pancreatic somatostatinoma 11.6 BRCA2 CDKN2A EGFR KRAS MUC4 SMAD4
30 glomus tympanicum tumor 11.6 BRCA2 CDKN1A CDKN2A EGF EGFR TP53
31 adult astrocytic tumour 11.6 CCND1 CDKN2A EGF EGFR KRAS TP53
32 villous adenoma 11.6 CCND1 CDKN1A CDKN2A EGF EGFR TP53
33 esophagus lymphoma 11.6 CCND1 CDKN1A CDKN2A EGFR KRAS TP53
34 giant cell glioblastoma 11.6 CCND1 CDKN1A CDKN2A EGF EGFR TP53
35 ductal carcinoma in situ 11.6 BRCA1 BRCA2 CCND1 CDKN2A EGFR TP53
36 estrogen-receptor negative breast cancer 11.6 BRCA1 BRCA2 CCND1 CDKN2A EGFR TP53
37 nasopharyngeal carcinoma 11.6 BRCA1 BRCA2 CDKN1A CDKN2A EGFR TP53
38 apocrine adenoma 11.6 BRCA1 BRCA2 CCND1 CDKN2A KRAS TP53
39 brown-vialetto-van laere syndrome 11.6 CCND1 CDKN2A EGFR KRAS TP53 VEGFA
40 zimmermann-laband syndrome 2 11.6 CCND1 CDKN2A EGF EGFR TP53 VEGFA
41 distal monosomy 7q36 11.6 BRCA1 BRCA2 EGFR TP53 VEGFA
42 ovarian brenner tumor 11.6 CDKN1A CDKN2A EGF EGFR TP53 VEGFA
43 dental caries 11.6 BRCA1 BRCA2 KRAS TP53 VEGFA
44 nasal cavity disease 11.6 BRCA1 BRCA2 KRAS TP53 VEGFA
45 endometriosis of uterus 11.5 CDKN2A EGFR KRAS TP53 VEGFA
46 advanced sleep phase syndrome 11.5 CDKN2A KRAS MUC4 SMAD4 TP53
47 post-surgical hypoinsulinemia 11.5 BRCA2 CCND1 CDKN1A CDKN2A TP53
48 acute porphyria 11.5 CCND1 CDKN2A EGFR KRAS TP53
49 retinal detachment 11.5 BRCA1 BRCA2 CDKN2A TP53
50 mantle cell lymphoma 11.5 CDKN2A EGF EGFR TP53 VEGFA

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Biliary Tract Neoplasm
Cholangitis Cholestasis
Deficiency Anemia Intestinal Obstruction
Pancreatic Agenesis 1 Pancreatitis, Hereditary
Protein-Energy Malnutrition Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Symptoms via clinical synopsis from OMIM:

54

Abdomen- Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma


Clinical features from OMIM:

260350

Human phenotypes related to Pancreatic Cancer:

32
id Description HPO Frequency HPO Source Accession
1 neoplasm of the pancreas 32 HP:0002894

UMLS symptoms related to Pancreatic Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas, pruritus

GenomeRNAi Phenotypes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.06 BRCA1 RBBP8
2 Decreased homologous recombination repair frequency GR00151-A-2 10.06 BRCA1 RBBP8
3 Decreased homologous recombination repair frequency GR00236-A-1 10.06 BRCA2 PALB2 RBBP8 BRCA1
4 Decreased homologous recombination repair frequency GR00236-A-2 10.06 BRCA2 PALB2 RBBP8 BRCA1
5 Decreased homologous recombination repair frequency GR00236-A-3 10.06 BRCA1 BRCA2 PALB2 RBBP8
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.84 CDKN1A CDKN2A PALB2 SST STK11 TP53
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.84 CDKN2A PALB2 SST STK11 TP53 BRCA1
8 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 BRCA1 BRCA2 CDKN1A PALB2 RBBP8 TP53

MGI Mouse Phenotypes related to Pancreatic Cancer:

44 (show all 26)
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.51 CDKN2A EGF EGFR KRAS SMAD4 SPINK1
2 growth/size/body region MP:0005378 10.51 EGFR KRAS PALB2 SMAD4 SPINK1 SST
3 cellular MP:0005384 10.49 STK11 TP53 VEGFA ACVR1B BRCA1 BRCA2
4 endocrine/exocrine gland MP:0005379 10.47 ACVR1B BRCA1 BRCA2 CCKBR CCND1 CDKN1A
5 immune system MP:0005387 10.46 BRCA1 BRCA2 CCKBR CCND1 CDKN1A CDKN2A
6 integument MP:0010771 10.45 ACVR1B BRCA1 BRCA2 CCKBR CCND1 CDKN1A
7 embryo MP:0005380 10.44 ACVR1B BRCA1 BRCA2 CDKN1A CDKN2A EGFR
8 homeostasis/metabolism MP:0005376 10.44 CCKBR CCND1 CDKN1A CDKN2A EGFR KRAS
9 mortality/aging MP:0010768 10.44 ACVR1B BRCA1 BRCA2 CCND1 CDKN1A CDKN2A
10 behavior/neurological MP:0005386 10.41 STK11 TP53 VEGFA BRCA1 BRCA2 CCKBR
11 cardiovascular system MP:0005385 10.4 BRCA1 CCKBR CCND1 CDKN1A CDKN2A EGFR
12 nervous system MP:0003631 10.36 CCND1 ACVR1B BRCA1 BRCA2 CCKBR CDKN1A
13 hematopoietic system MP:0005397 10.35 KRAS SMAD4 SPINK1 STK11 TP53 VEGFA
14 neoplasm MP:0002006 10.29 CDKN1A CDKN2A EGFR KRAS PALB2 RBBP8
15 craniofacial MP:0005382 10.26 CCND1 CDKN1A EGFR KRAS SMAD4 STK11
16 limbs/digits/tail MP:0005371 10.19 EGFR KRAS PALB2 SMAD4 TP53 VEGFA
17 liver/biliary system MP:0005370 10.18 CCKBR CDKN1A CDKN2A EGFR KRAS SMAD4
18 normal MP:0002873 10.18 ACVR1B BRCA1 BRCA2 CCND1 EGF EGFR
19 muscle MP:0005369 10.15 BRCA1 CDKN1A CDKN2A EGFR KRAS SMAD4
20 no phenotypic analysis MP:0003012 10.13 ACVR1B CDKN1A CDKN2A EGFR KRAS SPINK1
21 reproductive system MP:0005389 10.07 ACVR1B BRCA1 BRCA2 CCND1 CDKN1A CDKN2A
22 renal/urinary system MP:0005367 9.97 CDKN1A EGFR KRAS SMAD4 STK11 TP53
23 respiratory system MP:0005388 9.85 ACVR1B BRCA1 CCND1 CDKN1A CDKN2A EGFR
24 pigmentation MP:0001186 9.77 BRCA1 CDKN2A EGFR KRAS TP53
25 skeleton MP:0005390 9.73 EGFR KRAS SMAD4 SST TP53 VEGFA
26 vision/eye MP:0005391 9.28 CCND1 CDKN1A CDKN2A EGF EGFR KRAS

Drugs & Therapeutics for Pancreatic Cancer

FDA approved drugs:

(show all 6)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis March 2009
2
Erbitux 17 46 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
3
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
4
SecreFlo 17 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002
5
Sutent 17 46 SUNITINIB MALATE Pfizer May 2011/ January 2006
6
Tarceva 17 46 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 678)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
2
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 61825-94-3 5310940 9887054 43805 6857599
4
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
6
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
7
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
8
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
9
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
12
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
13
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
14
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
15
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
17
Iron Approved Phase 4,Phase 2 7439-89-6 23925
18
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
19
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
20
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
21
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
22
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
23
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
24
Etomidate Approved Phase 4 33125-97-2 36339 667484
25
Meperidine Approved Phase 4 57-42-1 4058
26
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
27
Nicotine Approved Phase 4 54-11-5 942 89594
28
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
29
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
30
Dexlansoprazole Approved Phase 4 138530-94-6, 103577-45-3 9578005
31
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
32
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
33
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
34
Desflurane Approved Phase 4 57041-67-5 42113
35
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
36
Thrombin Approved Phase 4
37
Tegafur Approved Phase 4,Phase 2,Phase 1 17902-23-7 5386
38
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
39 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
40
Butyric Acid Experimental Phase 4,Phase 1,Phase 2 107-92-6 264
41 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2277)

id Name Status NCT ID Phase Drugs
1 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
2 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
3 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
4 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
5 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
6 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
7 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
8 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer Completed NCT01346410 Phase 4
9 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
10 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
11 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
12 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
13 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
14 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
15 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
16 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
17 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
18 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
19 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
20 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
21 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
22 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
23 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
24 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
25 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
26 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
27 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection Completed NCT01914692 Phase 4 Somatostatin
28 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
29 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
30 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
31 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
32 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
33 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
34 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
35 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
36 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Active, not recruiting NCT02238847 Phase 4
37 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
38 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
39 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
40 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
41 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
42 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Not yet recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
43 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4 Albis®;Placebo
44 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
45 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
46 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
47 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
48 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
49 Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer Unknown status NCT02079623 Phase 3
50 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

id Genetic test Affiliating Genes
1 Carcinoma of Pancreas 29
2 Familial Pancreatic Carcinoma 29
3 Neoplasm of the Pancreas 29
4 Pancreatic Cancer, Somatic 24 SMAD4 KRAS
5 Pancreatic Cancer 24 STK11 TP53
6 Familial Pancreatic Cancer 24 KRAS

Anatomical Context for Pancreatic Cancer

MalaCards organs/tissues related to Pancreatic Cancer:

39
Pancreas, Liver, Lung, Testes, T Cells, Colon, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
id Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 4445)
id Title Authors Year
1
Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer. ( 28303855 )
2017
2
Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? ( 28085753 )
2017
3
Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling. ( 28377226 )
2017
4
CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. ( 28242758 )
2017
5
MicroRNAa89296 targets AKT2 in pancreatic cancer and functions as a potential tumor suppressor. ( 28534950 )
2017
6
ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca(2+)/RhoA pathway. ( 28518134 )
2017
7
Case report: Irreversible electroporation for locally advanced pancreatic cancer. ( 28941969 )
2017
8
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. ( 28086938 )
2017
9
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer. ( 28476815 )
2017
10
Effect of NR5A2 inhibition on pancreatic cancer stem cell (CSC) properties and epithelial-mesenchymal transition (EMT) markers. ( 27996162 )
2017
11
Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis. ( 28153717 )
2017
12
KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. ( 28595260 )
2017
13
Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine. ( 28521448 )
2017
14
Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis. ( 28079594 )
2017
15
CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2. ( 28954272 )
2017
16
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. ( 28131992 )
2017
17
The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand. ( 28476883 )
2017
18
SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells. ( 28351319 )
2017
19
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. ( 28081543 )
2017
20
Reproductive factors, exogenous hormone use, and risk of pancreatic cancer in postmenopausal women. ( 28521283 )
2017
21
Targeted Stroma in Pancreatic Cancer: Promises and Failures of Target Therapies. ( 28083912 )
2017
22
Active Systemic Treatment of Pancreatic Cancer. ( 28515255 )
2017
23
Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. ( 28349057 )
2017
24
Downregulation of the N-myc downstream regulated gene 1 is related to enhanced proliferation, invasion and migration of pancreatic cancer. ( 28075464 )
2017
25
Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. ( 28526679 )
2017
26
Postoperative inflammation as a possible cause of portal vein thrombosis after irreversible electroporation for locally advanced pancreatic cancer. ( 28932093 )
2017
27
KRAS/NF-I_B/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis. ( 27793842 )
2017
28
KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer. ( 28179576 )
2017
29
microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression. ( 28450156 )
2017
30
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. ( 28244632 )
2017
31
Methyl-CpG-binding domain 3 inhibits epithelial-mesenchymal transition in pancreatic cancer cells via TGF-I^/Smad signalling. ( 27898661 )
2017
32
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. ( 28092682 )
2017
33
Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine. ( 28535453 )
2017
34
Failure to Treat: Audit of an Institutional Cancer Registry Database at a Large Comprehensive Cancer Center Reveals Factors Affecting the Treatment of Pancreatic Cancer. ( 28534079 )
2017
35
USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway. ( 28286270 )
2017
36
ZNF281 Promotes Growth and Invasion of Pancreatic Cancer Cells by Activating Wnt/I^-Catenin Signaling. ( 28523575 )
2017
37
Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. ( 28089484 )
2017
38
MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. ( 28034748 )
2017
39
Gedunin inhibits pancreatic cancer by altering sonic hedgehog signaling pathway. ( 26988754 )
2017
40
Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. ( 28514751 )
2017
41
Isolation of circulating tumor cells in pancreatic cancer patients by immunocytochemical assay. ( 28523756 )
2017
42
The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation. ( 28114355 )
2017
43
Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. ( 28178665 )
2017
44
Role of CCL20 mediated immune cell recruitment in NF-I_B mediated TRAIL resistance of pancreatic cancer. ( 28188806 )
2017
45
Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer. ( 28223335 )
2017
46
miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. ( 28052003 )
2017
47
Psoriasin promotes invasion, aggregation and survival of pancreatic cancer cells; association with disease progression. ( 28393239 )
2017
48
Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer. ( 28002641 )
2017
49
Surgery for pancreatic cancer: critical radiologic findings for clinical decision making. ( 28948329 )
2017
50
Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey. ( 28087054 )
2017

Variations for Pancreatic Cancer

ClinVar genetic disease variations for Pancreatic Cancer:

6 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1 STK11 NM_000455.4(STK11): c.108C> A (p.Tyr36Ter) single nucleotide variant Pathogenic rs137853079 GRCh37 Chromosome 19, 1207020: 1207020
2 STK11 NM_000455.4(STK11): c.650delC (p.Pro217Argfs) deletion Pathogenic rs397518442 GRCh37 Chromosome 19, 1220632: 1220632
3 STK11 NM_000455.4(STK11): c.936delA (p.Lys312Asnfs) deletion Pathogenic rs397518443 GRCh37 Chromosome 19, 1222999: 1222999
4 ACVR1B NM_020328.3(ACVR1B): c.1282_1286delGATGA (p.Asp428Asnfs) deletion Pathogenic rs387906389 GRCh37 Chromosome 12, 52380624: 52380628
5 ACVR1B NM_020328.3(ACVR1B): c.1385-502_1515+24del deletion Pathogenic GRCh37 Chromosome 12, 52385145: 52385801
6 SMAD4 NM_005359.5(SMAD4): c.1072G> T (p.Gly358Ter) single nucleotide variant Pathogenic rs121912576 GRCh37 Chromosome 18, 48591909: 48591909
7 SMAD4 NM_005359.5(SMAD4): c.1477G> C (p.Asp493His) single nucleotide variant Pathogenic rs121912578 GRCh37 Chromosome 18, 48604655: 48604655
8 SMAD4 NM_005359.5(SMAD4): c.1543A> T (p.Arg515Ter) single nucleotide variant Pathogenic rs121912579 GRCh37 Chromosome 18, 48604721: 48604721
9 TP53 NM_000546.5(TP53): c.105G> T (p.Leu35Phe) single nucleotide variant Pathogenic rs121912661 GRCh37 Chromosome 17, 7579582: 7579582
10 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
11 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
12 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
13 SMAD4 NM_005359.5(SMAD4): c.1236C> G (p.Tyr412Ter) single nucleotide variant Pathogenic rs121912577 GRCh37 Chromosome 18, 48593485: 48593485

Cosmic variations for Pancreatic Cancer:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM520 KRAS